Literature DB >> 16706806

Review of genetic and epigenetic alterations in hepatocarcinogenesis.

Nirmitha I Herath1, Barbara A Leggett, Graeme A MacDonald.   

Abstract

Hepatocellular carcinoma (HCC) is associated with multiple risk factors and is believed to arise from pre-neoplastic lesions, usually in the background of cirrhosis. However, the genetic and epigenetic events of hepatocarcinogenesis are relatively poorly understood. HCC display gross genomic alterations, including chromosomal instability (CIN), CpG island methylation, DNA rearrangements associated with hepatitis B virus (HBV) DNA integration, DNA hypomethylation and, to a lesser degree, microsatellite instability. Various studies have reported CIN at chromosomal regions, 1p, 4q, 5q, 6q, 8p, 10q, 11p, 16p, 16q, 17p and 22q. Frequent promoter hypermethylation and subsequent loss of protein expression has also been demonstrated in HCC at tumor suppressor gene (TSG), p16, p14, p15, SOCS1, RIZ1, E-cadherin and 14-3-3 sigma. An interesting observation emerging from these studies is the presence of a methylator phenotype in hepatocarcinogenesis, although it does not seem advantageous to have high levels of microsatellite instability. Methylation also appears to be an early event, suggesting that this may precede cirrhosis. However, these genes have been studied in isolation and global studies of methylator phenotype are required to assess the significance of epigenetic silencing in hepatocarcinogenesis. Based on previous data there are obvious fundamental differences in the mechanisms of hepatic carcinogenesis, with at least two distinct mechanisms of malignant transformation in the liver, related to CIN and CpG island methylation. The reason for these differences and the relative importance of these mechanisms are not clear but likely relate to the etiopathogenesis of HCC. Defining these broad mechanisms is a necessary prelude to determine the timing of events in malignant transformation of the liver and to investigate the role of known risk factors for HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16706806     DOI: 10.1111/j.1440-1746.2005.04043.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  55 in total

1.  Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure.

Authors:  Yu-Jing Zhang; Hui-Chen Wu; Hulya Yazici; Ming-Whei Yu; Po-Huang Lee; Regina M Santella
Journal:  World J Hepatol       Date:  2012-05-27

Review 2.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

3.  Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested case-control study.

Authors:  Hui-Chen Wu; Qiao Wang; Hwai-I Yang; Wei-Yann Tsai; Chien-Jen Chen; Regina M Santella
Journal:  Carcinogenesis       Date:  2012-05-12       Impact factor: 4.944

4.  Blood DNA methylation markers in prospectively identified hepatocellular carcinoma cases and controls from Taiwan.

Authors:  Hui-Chen Wu; Jing Shen; Hwai-I Yang; Wei-Yann Tsai; Chien-Jen Chen; Regina M Santella
Journal:  World J Hepatol       Date:  2016-02-18

5.  RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage.

Authors:  A Kathleen McClendon; Jeffry L Dean; Adam Ertel; Zhiyan Fu; Dayana B Rivadeneira; Christopher A Reed; Ryan J Bourgo; Agnieszka Witkiewicz; Sankar Addya; Christopher N Mayhew; H Leighton Grimes; Paolo Fortina; Erik S Knudsen
Journal:  Gastroenterology       Date:  2011-06-24       Impact factor: 22.682

6.  miR-185 inhibits hepatocellular carcinoma growth by targeting the DNMT1/PTEN/Akt pathway.

Authors:  Ximena V Qadir; Chang Han; Dongdong Lu; Jinqiang Zhang; Tong Wu
Journal:  Am J Pathol       Date:  2014-06-06       Impact factor: 4.307

Review 7.  Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Giovanni Targher
Journal:  Ann Transl Med       Date:  2017-07

8.  The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.

Authors:  Brigette B Y Ma; Fion Sung; Qian Tao; Fan Fong Poon; Vivian W Lui; Winnie Yeo; Stephen L Chan; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2009-01-27       Impact factor: 3.850

Review 9.  Promoter methylation in the genesis of gastrointestinal cancer.

Authors:  Clement Richard Boland; Sung Kwan Shin; Ajay Goel
Journal:  Yonsei Med J       Date:  2009-06-23       Impact factor: 2.759

10.  Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.

Authors:  Hector Hernandez-Vargas; Marie-Pierre Lambert; Florence Le Calvez-Kelm; Géraldine Gouysse; Sandrine McKay-Chopin; Sean V Tavtigian; Jean-Yves Scoazec; Zdenko Herceg
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.